(Total Views: 251)
Posted On: 02/28/2022 8:47:18 AM
Post# of 110
Theralink® Technologies Announces Change of Ticker Symbol and CUSIP
DENVER , Feb. 25, 2022 /PRNewswire/ -- Theralink Technologies (OTC: THER) ("Theralink" or the "Company"
announces today that it has received approval for its previously announced name change and a change of its ticker symbol from "OBMP" to "THER," as announced by the Financial Industry Regulatory Authority (FINRA) on its February 24, 2022 daily list. The Company's common stock will start trading under this new ticker symbol on February 25, 2022 . As is customary with a ticker symbol change, the CUSIP number for the Company's shares was also changed to 88339Q109. In addition, the approval further means that the Company is again able to issue shares of its common stock, which it had temporarily suspended during the pendency of the corporate action.
Mick Ruxin , M.D., Theralink's President & CEO stated "This milestone allows us to pursue numerous administrative and business initiatives going forward. We are very excited about our company's future prospects in potentially decreasing the morbidity and mortality of cancer patients."
DENVER , Feb. 25, 2022 /PRNewswire/ -- Theralink Technologies (OTC: THER) ("Theralink" or the "Company"
announces today that it has received approval for its previously announced name change and a change of its ticker symbol from "OBMP" to "THER," as announced by the Financial Industry Regulatory Authority (FINRA) on its February 24, 2022 daily list. The Company's common stock will start trading under this new ticker symbol on February 25, 2022 . As is customary with a ticker symbol change, the CUSIP number for the Company's shares was also changed to 88339Q109. In addition, the approval further means that the Company is again able to issue shares of its common stock, which it had temporarily suspended during the pendency of the corporate action. Mick Ruxin , M.D., Theralink's President & CEO stated "This milestone allows us to pursue numerous administrative and business initiatives going forward. We are very excited about our company's future prospects in potentially decreasing the morbidity and mortality of cancer patients."
(0)
(0)
